Healthcare Industry News:  antiviral 

Biopharmaceuticals Oncology Personnel

 News Release - February 28, 2007

Hana Biosciences Appoints Lyn Wiesinger to Board of Directors

SOUTH SAN FRANCISCO, Calif.--(HSMN NewsFeed)--Hana Biosciences (NASDAQ:HNAB ), a biopharmaceutical company focused on advancing cancer care, today announced the appointment of Lyn Wiesinger to its Board of Directors. Her career has encompassed leadership roles at Pfizer, Rhone-Poulenc Rorer, Bristol-Myers Squibb and Vicuron Pharmaceuticals.

"We are extremely pleased to have Ms. Wiesinger, a seasoned pharmaceutical and biotech industry veteran, join our Board of Directors," stated Mark Ahn, Ph.D., President and Chief Executive Officer. "With more than 20 years of pharmaceutical operating experience, Ms Wiesinger's wealth of industry management, development and commercial expertise make her an excellent addition to Hana's Board."

Ms. Wiesinger has extensive operating experience in the pharmaceutical and biotechnology industry in both global and US roles. Most recently, she was Senior Vice President of Marketing and Market Development at Vicuron Pharmaceuticals, a biotechnology company in the specialty hospital market, where she initiated and lead the company's commercial function. She subsequently played an integral role in Vicuron's sale to Pfizer Inc. in September 2005. Prior to joining Vicuron, Ms. Wiesinger held senior positions at Bristol-Myers Squibb including Vice President, US Cardiovascular Marketing, where she lead the pre-launch program and marketing team for Vanlev, a novel antihypertensive and CHF treatment and Vice President, Global Marketing, Infectious Diseases, where she was responsible for managing the company's worldwide portfolio of antibiotics, antivirals and antifungals. Ms. Wiesinger established her early career in pharmaceuticals with an extensive tenure at Pfizer Inc., during which she held a broad range of management positions in new product development and marketing, marked by her leadership of the successful worldwide development and launch of Diflucan. Ms Wiesinger began her career as a consultant at Booz Allen and Hamilton. She holds an MBA degree from the Wharton School and a BA degree in psychology from the University of Pennsylvania.

About Hana Biosciences, Inc.

Hana Biosciences, Inc. (NASDAQ:HNAB ) is a South San Francisco, CA-based biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to advance cancer care. The company is committed to creating value by building a world-class team, accelerating the development of lead product candidates, expanding its pipeline by being the alliance partner of choice, and nurturing a unique company culture. Additional information on Hana Biosciences can be found at www.hanabiosciences.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that could cause Hana's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as ``anticipates,'' ``expects,'' ``plans,'' ``believes,'' ``intends,'' and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Hana's development efforts relating to its product candidates will be successful. Other risks that may affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of Hana's product candidates, the risk that the results of clinical trials may not support Hana's claims, Hana's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2006 filed with the Securities and Exchange Commission. Hana assumes no obligation to update these statements, except as required by law.


Source: Hana Biosciences

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.